Sacituzumab Govitecan-Hziy (Trodelvy)
April 2021
in “
Oncology Times
”
TLDR Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
Sacituzumab govitecan-hziy (Trodelvy™) was an antibody-drug conjugate used for treating adult patients with metastatic triple-negative breast cancer (TNBC) who had previously received two or more therapies for metastatic disease. It worked by binding to Trop-2 receptors on cancer cells, delivering the topoisomerase 1 inhibitor SN-38 to induce cell death. The IMMU-132-01 Phase I/II trial, which included 108 patients with metastatic TNBC, showed an overall response rate of 33.3%, with a median response duration of 7.7 months. Common side effects included nausea, diarrhea, neutropenia, and alopecia. The drug required premedication to prevent infusion reactions and chemotherapy-induced nausea and vomiting. It was administered intravenously on a 21-day cycle, with specific precautions for patients with certain genetic profiles and those experiencing severe side effects like neutropenia and diarrhea.
